6533b86cfe1ef96bd12c8129

RESEARCH PRODUCT

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs

Raffaella PasqualeGiuseppe RossiNicola VianelliSilvia CantoniMariella D'addaMarco RuggeriBruno FattizzoMonica CarpenedoGiuseppe AuteriDoriana GramegnaSergio SiragusaMariasanta NapolitanoDario ConsonniWilma Barcellini

subject

MaleOncologymedicine.medical_specialtyRecombinant Fusion ProteinsEltrombopagBone Marrow CellsImmune Thrombocytopenic PurpuraReceptors FcBenzoateschemistry.chemical_compoundInternal medicinemedicineHumansOnline Only ArticlesThrombopoietinRetrospective StudiesPurpura Thrombocytopenic IdiopathicRomiplostimbusiness.industryRetrospective cohort studyromiplostimHematologyMiddle AgedImmune thrombocytopeniaClinical trialHydrazinesmedicine.anatomical_structureThrombopoietinchemistryCohortPyrazolesFemaleBone marroweltrombopagbusinessFollow-Up Studiesmedicine.drug

description

It is well established that immune thrombocytopenia (ITP) results from increased immune mediated platelet destruction (anti-platelets antibodies, autoreactive T cells, and reduction of regulatory T cells) along with impaired production in the bone marrow.1 The latter has been attributed to both cellular and humoral mediators that cause suppression of megakaryocyte production and maturation.2 Current standard first line therapy consists of corticosteroids, with or without intravenous Ig, achieving about 70-80% response rate. However, a consistent proportion of patients would relapse after corticosteroid discontinuation or tapering, and requires further therapy. ...

yearjournalcountryeditionlanguage
2019-10-01Haematologica
https://doi.org/10.3324/haematol.2019.216804